Literature DB >> 8724310

Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block.

C E Tseng1, K Caldwell, S Feit, E K Chan, J P Buyon.   

Abstract

OBJECTIVE: To compare the subclass distribution of anti-48 kDa La(SSB) and anti-52 and 60 kDa Ro(SSA) antibodies in the maternal and neonatal circulation, in pregnancies affected and unaffected by the development of congenital heart block (CHB).
METHODS: Sera were obtained from 32 mothers (during 34 pregnancies 23 complicated by CHB and 11 healthy) demonstrated to have anti-Ro(SSA) and/or La(SSB). Maternal and neonatal autoantibodies were evaluated for subclass distribution by ELISA:
RESULTS: All 4 subclasses of anti-Ro(SSA) and La(SSB) antibodies cross the placenta and are detectable in sera obtained from the umbilical cord, IgG1 and IgG3 were the major subclasses represented in the 48 kDa La(SSB) and 52 kDa Ro(SSA) responses. All subclasses, including IgG2 and IgG4, were observed in about one-third of the anti-52 kDa Ro(SSA) and 48 kDa La(SSB) responses. In contrast, anti-60 kDa antibodies were, with rare exception, confined to IgG1. Except for anti-48 kDa La(SSB) IgG3 antibodies, no significant differences were observed between affected and unaffected pregnancies in the ratio of maternal to neonatal levels of any of the antibody subclasses. Overall, there were no significant differences in the subclass profiles between mothers whose children had heart block and those who did not.
CONCLUSION: The IgG subclasses of anti-48 kDa La(SSB) and anti-52 and 60 kDa Ro(SSA) do not account for the susceptibility of one fetus versus another for the development of CHB. Anti-60 kDa Ro(SSA) antibodies are more restricted in subclass distribution than anti-52 kDA Ro(SSA) or 48 kDa La(SSB) responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724310

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

Review 2.  Neonatal lupus.

Authors:  Antonio Brucato; Rolando Cimaz; Marco Stramba-Badiale
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

3.  Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus.

Authors:  Amit Saxena; Erin McDonnell; Paula S Ramos; Satria Sajuthi; Miranda C Marion; Carl D Langefeld; Jill P Buyon; Robert M Clancy
Journal:  Arthritis Rheum       Date:  2012-03

4.  Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.

Authors:  Deborah M Friedman; Carolina Llanos; Peter M Izmirly; Brigit Brock; John Byron; Joshua Copel; Karen Cummiskey; Mary Anne Dooley; Jill Foley; Cornelia Graves; Colleen Hendershott; Richard Kates; Elena V Komissarova; Michelle Miller; Emmanuelle Paré; Colin K L Phoon; Tracy Prosen; Dale Reisner; Eric Ruderman; Philip Samuels; Jerry K Yu; Mimi Y Kim; Jill P Buyon
Journal:  Arthritis Rheum       Date:  2010-04

5.  Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block.

Authors:  Robert M Clancy; David Alvarez; Elena Komissarova; Franck J Barrat; Jordan Swartz; Jill P Buyon
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

6.  Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.

Authors:  Carolina Llanos; Peter M Izmirly; Margaret Katholi; Robert M Clancy; Deborah M Friedman; Mimi Y Kim; Jill P Buyon
Journal:  Arthritis Rheum       Date:  2009-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.